Boston Scientific and BioForm Medical Announce FDA Approval of Coaptite(R) Injectable Implant
Posted on: Wednesday, 10 May 2006, 15:04 CDT
NATICK, Mass. and SAN MATEO, Calif, May 10 /PRNewswire-FirstCall/ -- Boston Scientific Corporation and BioForm Medical, Inc. today announced United States Food and Drug Administration approval of BioForm Medical's Coaptite Injectable Implant for the treatment of female stress urinary incontinence. The companies also announced that they have signed an agreement giving Boston Scientific exclusive distribution rights for the Coaptite Injectable Implant in the United States. The product is expected to launch in the U.S. immediately.
"Boston Scientific is excited to distribute this next-generation bulking agent," said Eric Goorno, President of the Urology and Gynecology businesses at Boston Scientific. "This agent is designed to offer the durability of a synthetic product in addition to procedural ease-of-use. Coaptite is a natural strategic fit for our women's health business and rounds out our product offering for the treatment of stress urinary incontinence."
"Approval for Coaptite Injectable Implant and our new relationship with Boston Scientific are important milestones for BioForm Medical," said Steven Basta, President and Chief Executive Officer of BioForm. "We believe that Boston Scientific is the ideal distributor for the Coaptite Injectable Implant. Their strong presence and experience in offering the market different treatment options for female stress urinary incontinence will be instrumental in positioning Coaptite Injectable Implant as a leader in the bulking market."
The Coaptite Injectable Implant is a next-generation bulking agent. Clinical trial results indicated fewer re-injections and less material volume versus other approved bulking agents while maintaining the durability characteristics of a synthetic product. The combination of calcium hydroxylapatite particles and the sodium carboxymethylcellulose carrier gel form a scaffold that promotes tissue infiltration. The Coaptite Injectable Implant particles are composed of the same components that are found in bone and teeth and are biocompatible.
Clinical trial results
BioForm Medical also announced results from a multi-center clinical study for the treatment of stress urinary incontinence comparing the use of Coaptite Injectable Implant versus bovine collagen. Coaptite Injectable Implant demonstrated that 63 percent of patients treated with Coaptite Injectable Implant were improved at 12 months. Coaptite Injectable Implant also demonstrated that total implant volumes were significantly less (p<0.0001) versus the control group (4 ml vs. 6.8 ml).
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/.
This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, reimbursement policies, commercialization of new technologies, litigation, the Company's overall business strategy and other factors described in the Company's filings with the Securities and Exchange Commission.
CONTACT: Milan Kofol 508-650-8569 (Office) Investor Relations Boston Scientific Corporation Paul Donovan 508-650-8541 (Office) Media Relations Boston Scientific Corporation Adam Gridley 650-286-4025 (Office) Corporate Development BioForm Medical, Inc.
Boston Scientific Corporation
CONTACT: Milan Kofol, Investor Relations, +1-508-650-8569, or PaulDonovan, Media Relations, +1-508-650-8541, both of Boston ScientificCorporation; or Adam Gridley of BioForm Medical, Inc., +1-650-286-4025
Web site: http://www.bostonscientific.com/
Source: PRNewswire-FirstCall
Related Articles
- North American Scientific to Divest Non-Therapeutic Product Line
- Crucell to Relocate Dukoral and rCTB Bulk Production Sites
- FDA Issues Not-Approvable Letter for Lilly's Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
- FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
- Vaginal Progesterone is Equally Effective and Results in Lower Miscarriage Rates Than Injectable Progesterone in Infertility Treatment
- Lilly Files for European Approval of ALIMTA(R) (Pemetrexed for Injection) for First-Line Treatment of Non-Small Cell Lung Cancer
- FDA Accepts NDA Filing for Cleviprex(TM) (Clevidipine Butyrate Injectable Emulsion) for the Treatment of Acute Hypertension
- Boston Scientific Purchases Prostate Treatment Technology From Celsion Corporation
- Vasomedical to Launch Lumenair EECP Therapy System at American Heart Association Scientific Sessions; New Treatment Option for Angina and Heart Failure Patients
User Comments (0)
RSS Feeds